Xavier Norel

List of Publications by Year
in descending order

116 papers	5,887 citations	94433 37 h-index	74163 75 g-index
120 all docs	120 docs citations	120 times ranked	8924 citing authors

#	Article	IF	Citations
1	The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. British Journal of Pharmacology, 2015, 172, 6024-6109.	5.4	521
2	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	5.4	519
3	The Concise Guide to PHARMACOLOGY 2015/16: G proteinâ€coupled receptors. British Journal of Pharmacology, 2015, 172, 5744-5869.	5.4	507
4	Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. Cell, 2017, 168, 1086-1100.e10.	28.9	420
5	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	5.4	337
6	The Concise Guide to PHARMACOLOGY 2015/16: Overview. British Journal of Pharmacology, 2015, 172, 5729-5743.	5.4	220
7	The Concise Guide to PHARMACOLOGY 2015/16: Transporters. British Journal of Pharmacology, 2015, 172, 6110-6202.	5.4	190
8	The Concise Guide to PHARMACOLOGY 2015/16: Voltageâ€gated ion channels. British Journal of Pharmacology, 2015, 172, 5904-5941.	5.4	176
9	The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors. British Journal of Pharmacology, 2015, 172, 5979-6023.	5.4	158
10	The Concise Guide to PHARMACOLOGY 2015/16: Ligandâ€gated ion channels. British Journal of Pharmacology, 2015, 172, 5870-5903.	5.4	133
11	The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukotrienes and Essential Fatty Acids, 2013, 89, 55-63.	2.2	122
12	Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988. European Journal of Pharmacology, 1986, 123, 197-205.	3.5	119
13	The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. British Journal of Pharmacology, 2015, 172, 5956-5978.	5.4	119
14	Prostanoid receptors involved in the relaxation of human pulmonary vessels. British Journal of Pharmacology, 1999, 126, 859-866.	5.4	109
15	Prostanoid Receptors in the Human Vascular Wall. Scientific World Journal, The, 2007, 7, 1359-1374.	2.1	106
16	A second cysteinyl leukotriene receptor in human lung. Journal of Pharmacology and Experimental Therapeutics, 1992, 263, 800-5.	2.5	106
17	Role of MMP-1 (-519A/G, -1607 1G/2G), MMP-3 (Lys45Glu), MMP-7 (-181A/G), and MMP-12 (-82A/G) Variants and Plasma MMP Levels on Obesity-Related Phenotypes and Microvascular Reactivity in a Tunisian Population. Disease Markers, 2017, 2017, 1-16.	1.3	91
18	The Cyclooxygenase-2â€“Prostaglandin E₂ Pathway Maintains Senescence of Chronic Obstructive Pulmonary Disease Fibroblasts. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 703-714.	5.6	90

#	Article	IF	Citations
19	Prostanoid receptors involved in the relaxation of human bronchial preparations. British Journal of Pharmacology, 1999, 126, 867-872.	5.4	78
20	M₁ and M₃ muscarinic receptors in human pulmonary arteries. British Journal of Pharmacology, 1996, 119, 149-157.	5.4	72
21	Vasorelaxation induced by prostaglandin E₂ in human pulmonary vein: role of the EP₄ receptor subtype. British Journal of Pharmacology, 2008, 154, 1631-1639.	5.4	67
22	Prostanoid EP₁â€•and TPâ€•receptors involved in the contraction of human pulmonary veins. British Journal of Pharmacology, 2001, 134, 1671-1678.	5.4	64
23	Silver Nanoparticles Impair Retinoic Acid-Inducible Gene I-Mediated Mitochondrial Antiviral Immunity by Blocking the Autophagic Flux in Lung Epithelial Cells. ACS Nano, 2018, 12, 1188-1202.	14.6	56
24	PGE2 receptor (EP4) agonists: Potent dilators of human bronchi and future asthma therapy?. Pulmonary Pharmacology and Therapeutics, 2012, 25, 115-118.	2.6	52
25	Degradation of acetylcholine in human airways: role of butyrylcholinesterase. British Journal of Pharmacology, 1993, 108, 914-919.	5.4	51
26	Human perivascular adipose tissue dysfunction as a cause of vascular disease: Focus on vascular tone and wall remodeling. European Journal of Pharmacology, 2015, 766, 16-24.	3.5	49
27	Control of human vascular tone by prostanoids derived from perivascular adipose tissue. Prostaglandins and Other Lipid Mediators, 2013, 107, 13-17.	1.9	48
28	Inhibitory effects of BAY u3405 on prostanoidâ€•induced contractions in human isolated bronchial and pulmonary arterial muscle preparations. British Journal of Pharmacology, 1991, 104, 591-595.	5.4	47
29	Prostacyclin modulation of contractions of the human pulmonary artery by cysteinylâ€“leukotrienes. European Journal of Pharmacology, 2000, 401, 389-395.	3.5	47
30	Inhibition of microsomal PGE synthaseâ€•1 reduces human vascular tone by increasing PGI₂: a safer alternative to COXâ€•2 inhibition. British Journal of Pharmacology, 2017, 174, 4087-4098.	5.4	46
31	Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONO-AE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins and Other Lipid Mediators, 2004, 74, 101-112.	1.9	45
32	The muscarinic receptor subtypes in human blood vessels. Therapie, 2001, 56, 223-6.	1.0	43
33	Anaphylactic bronchoconstriction in BP2 mice: interactions between serotonin and acetylcholine. British Journal of Pharmacology, 1999, 126, 312-316.	5.4	41
34	The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues. , 2004, 103, 81-94.		41
35	Functional Studies of Leukotriene Receptors in Vascular Tissues. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S107-S111.	5.6	40
36	The Concise Guide to PHARMACOLOGY 2015/16: Other ion channels. British Journal of Pharmacology, 2015, 172, 5942-5955.	5.4	40

#	Article	IF	Citations
37	Evidence for a M₁ muscarinic receptor on the endothelium of human pulmonary veins. British Journal of Pharmacology, 2000, 130, 73-78.	5.4	38
38	Pharmacological evidence for a novel cysteinylâ€leukotriene receptor subtype in human pulmonary artery smooth muscle. British Journal of Pharmacology, 2002, 137, 1339-1345.	5.4	38
39	Differential reactivity of human mammary artery and saphenous vein to prostaglandin E₂: Implication for cardiovascular grafts. British Journal of Pharmacology, 2011, 163, 826-834.	5.4	37
40	A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. Prostaglandins and Other Lipid Mediators, 2013, 107, 48-55.	1.9	37
41	Relaxation of isolated human pulmonary muscle preparations with prostacyclin (PGI2) and its analogs. Prostaglandins, 1987, 33, 845-854.	1.2	36
42	Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone. British Journal of Pharmacology, 2004, 142, 788-796.	5.4	36
43	Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia. Cardiovascular Research, 2018, 114, 1656-1666.	3.8	34
44	Selective cyclooxygenase-2 inhibition directly increases human vascular reactivity to norepinephrine during acute inflammation. Cardiovascular Research, 2008, 81, 269-277.	3.8	30
45	Antagonist resistant contractions of the porcine pulmonary artery by cysteinyl-leukotrienes. European Journal of Pharmacology, 2000, 401, 381-388.	3.5	29
46	Vasorelaxant effects of atrial peptide II on isolated human pulmonary muscle preparations. European Journal of Pharmacology, 1988, 150, 397-400.	3.5	28
47	Modulation of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries and veins. Acta Physiologica Scandinavica, 2002, 174, 9-15.	2.2	26
48	Reverse Regulatory Pathway (H2S / PGE2 / MMP) in Human Aortic Aneurysm and Saphenous Vein Varicosity. PLoS ONE, 2016, 11, e0158421.	2.5	26
49	International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E₂Receptors (EP1â€“4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions. Pharmacological Reviews, 2020, 72, 910-968.	16.0	26
50	Decreased PGE2 Content Reduces MMP-1 Activity and Consequently Increases Collagen Density in Human Varicose Vein. PLoS ONE, 2014, 9, e88021.	2.5	25
51	Prostanoid EP2 Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells. International Journal of Molecular Sciences, 2018, 19, 2372.	4.1	24
52	Histamine receptors on human isolated pulmonary arterial muscle preparations: effects of endothelial cell removal and nitric oxide inhibitors. Journal of Pharmacology and Experimental Therapeutics, 1992, 260, 762-7.	2.5	23
53	Prostaglandin E2 receptor subtypes in human blood and vascular cells. European Journal of Pharmacology, 2012, 695, 1-6.	3.5	22
54	MMPs and TIMPs levels are correlated with anthropometric parameters, blood pressure, and endothelial function in obesity. Scientific Reports, 2021, 11, 20052.	3.3	21

#	Article	IF	Citations
55	Endothelin-1 modulates cyclic GMP production and relaxation in human pulmonary vessels. Journal of Pharmacology and Experimental Therapeutics, 1995, 274, 969-75.	2.5	21
56	(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. Journal of Pharmacology and Experimental Therapeutics, 1994, 268, 868-72.	2.5	21
57	Cholinesterase activity in human pulmonary arteries and veins. British Journal of Pharmacology, 1997, 121, 986-990.	5.4	20
58	EFFECTS OF VARIOUS PHARMACOLOGICAL AGENTS ON ISOLATED HUMAN BRONCHIAL AND PULMONARY ARTERIAL AND VENOUS MUSCLE PREPARATIONS CONTRACTED BY LEUKOTRIENE D₄. Fundamental and Clinical Pharmacology, 1987, 1, 433-444.	1.9	19
59	Prostanoids in the pathophysiology of human coronary artery. Prostaglandins and Other Lipid Mediators, 2017, 133, 20-28.	1.9	19
60	A new mRNA splice variant coding for the human EP3-I receptor isoform. Prostaglandins Leukotrienes and Essential Fatty Acids, 2007, 77, 195-201.	2.2	17
61	Cholinesterase activity in pig airways and epithelial cells. Fundamental and Clinical Pharmacology, 1997, 11, 201-205.	1.9	14
62	Prostaglandin E2 induced contraction of human intercostal arteries is mediated by the EP3 receptor. European Journal of Pharmacology, 2012, 681, 55-59.	3.5	14
63	Inflammation increases MMP levels via PGE2 in human vascular wall and plasma of obese women. International Journal of Obesity, 2019, 43, 1724-1734.	3.4	14
64	Magnetic wire active microrheology of human respiratory mucus. Soft Matter, 2021, 17, 7585-7595.	2.7	14
65	Altered reactivity to norepinephrine through COX-2 induction by vascular injury in hypercholesterolemic rabbits. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H1882-H1888.	3.2	13
66	Bronchodilation induced by PGE 2 is impaired in Group III pulmonary hypertension. British Journal of Pharmacology, 2020, 177, 161-174.	5.4	13
67	Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents. Prostaglandins and Other Lipid Mediators, 2015, 121, 46-52.	1.9	12
68	Omega-3 polyunsaturated fatty acids reduce vascular tone and inflammation in human saphenous vein. Prostaglandins and Other Lipid Mediators, 2017, 133, 29-34.	1.9	11
69	Evaluation of some prostaglandins modulators on rat corpus cavernosum in-vitro: Is relaxation negatively affected by COX-inhibitors?. Biomedicine and Pharmacotherapy, 2019, 111, 1458-1466.	5.6	11
70	Cysteinyl-leukotriene receptors in pulmonary vessels. Journal of Physiology and Pharmacology, 1999, 50, 567-73.	1.1	11
71	Cysteinyl leukotriene receptors in the human lung: what's new?. Trends in Pharmacological Sciences, 1996, 17, 342-345.	8.7	10
72	Decreased vasorelaxation induced by iloprost during acute inflammation in human internal mammary artery. European Journal of Pharmacology, 2017, 804, 31-37.	3.5	10

#	Article	IF	Citations
73	Response to Anti-human IgE in Human Pulmonary Arteries: Regulation by Endothelium. The American Review of Respiratory Disease, 1993, 147, 1029-1033.	2.9	9
74	Absence of inflammatory conditions in human varicose saphenous veins. Inflammation Research, 2013, 62, 299-308.	4.0	9
75	Mechanism of thromboxane receptor-induced vasoconstriction in human saphenous vein. Prostaglandins and Other Lipid Mediators, 2020, 151, 106476.	1.9	8
76	Antigen-Induced Contraction of Human Isolated Lung Preparations Passively Sensitized with Monoclonal IgE: Effects of Indomethacin. International Archives of Allergy and Immunology, 1991, 96, 368-375.	2.1	6
77	Effects of Î²₂â€adrenoceptor agonists on antiâ€IgEâ€induced contraction and smooth muscle reactivity in human airways. British Journal of Pharmacology, 1995, 114, 935-940.	5.4	6
78	Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension. Biochemical Pharmacology, 2019, 166, 242-252.	4.4	6
79	Potassium channels modulate the action but not the synthesis of hydrogen sulfide in rat corpus cavernosum. Life Sciences, 2017, 189, 39-43.	4.3	5
80	Interaction between PGI2 and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients. Prostaglandins and Other Lipid Mediators, 2020, 146, 106388.	1.9	5
81	Antigenic Contraction of Guinea Pig Tracheal Preparations Passively Sensitized with Monoclonal IgE: Pharmacological Modulation. International Archives of Allergy and Immunology, 1988, 87, 342-348.	2.1	4
82	Effect of cold storage on cholinergic responses induced by electrical field stimulation in human bronchi. Pulmonary Pharmacology and Therapeutics, 2006, 19, 297-302.	2.6	4
83	Involvement of prostaglandin F2Î± in preeclamptic human umbilical vein vasospasm: a role of prostaglandin F and thromboxane A2 receptors. Journal of Hypertension, 2010, 28, 2438-2445.	0.5	4
84	Downregulation of PGI2 pathway in Pulmonary Hypertension Group-III patients. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 160, 102158.	2.2	4
85	Comparison of BN 52021, a new inhibitor of PAF-acether-induced platelet aggregation, with kadsurenone and CV 3988. Prostaglandins, 1985, 30, 701.	1.2	3
86	Cholinesterase inhibition by vecuronium and pancuronium in human airways. Life Sciences, 1994, 55, PL261-PL266.	4.3	3
87	ROLE OF NITRIC OXIDE ON CHOLINERGIC COMPONENT OF BRONCHIAL TONE IN PIG. Pharmacological Research, 1996, 34, 157-160.	7.1	3
88	Gorenne et al. reply. Trends in Pharmacological Sciences, 1997, 18, 148-149.	8.7	3
89	Hypoactivity of rat detrusor muscle in a model of cystitis: exacerbation by non-selective COX inhibitors and amelioration by a selective DP1 receptor antagonist. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 437-450.	3.0	3
90	Polymorphisms rs2745557 in PTGS2 and rs2075797 in PTGER2 are associated with the risk of chronic obstructive pulmonary disease development in a Tunisian cohort. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 166, 102252.	2.2	3

#	Article	IF	Citations
91	Comparative study of coronary artery bypass graft materials: reduced contraction and ADMA levels in internal mammary artery versus saphenous vein. Journal of Cardiovascular Surgery, 2022, 63, .	0.6	3
92	The Contraction of the Human Pulmonary Artery by LTC4 is Resistant to CYSLT1 Antagonists and Counteracted by Prostacyclin Release. Advances in Experimental Medicine and Biology, 2002, 507, 315-319.	1.6	3
93	Prostanoid receptors (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2020, 2020, .	0.2	3
94	Cysteinyl leukotriene receptors in the human lung: what's new?. Trends in Pharmacological Sciences, 1996, 17, 342-5.	8.7	3
95	Anti-IgE Response in Human Airways: Relative Contribution of Inflammatory Mediators. Mediators of Inflammation, 1994, 3, 359-363.	3.0	2
96	Cholinesterase activity in human pulmonary arteries and veins: correlation with mRNA levels. Life Sciences, 2005, 76, 2211-2220.	4.3	2
97	Sildenafil corrects the increased contractility of rat detrusor muscle induced by alprostadil in vitro. Pharmacological Reports, 2019, 71, 659-668.	3.3	2
98	Prostanoid receptors in GtoPdb v.2021.2. IUPHAR/BPS Guide To Pharmacology CITE, 2021, 2021, .	0.2	2
99	Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	2
100	Comparative study on the effect of aspirin, TP receptor antagonist and TxA2 synthase inhibitor on the vascular tone of human saphenous vein and internal mammary artery. Life Sciences, 2021, 286, 120073.	4.3	2
101	Contraction of Bovine Isolated Bronchial Airways: Effects of Epithelium Removal. Respiration, 1993, 60, 351-353.	2.6	1
102	Editorial. Prostaglandins and Other Lipid Mediators, 2015, 121, 1-3.	1.9	1
103	In search of pulmonary hypertension treatments: Effect of 17Î²-estradiol on PGI2 pathway in human pulmonary artery. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 172, 102321.	2.2	1
104	Responsiveness and sensitivity to cholinergic agonists and antagonists in bovine isolated bronchial muscles. Pharmacological Research, 1990, 22, 64-65.	7.1	0
105	The effects of cholinergic antagonists on bovine isolated bronchial muscles with and without epithelium. Pharmacological Research, 1990, 22, 315.	7.1	0
106	Muscarinic receptors in human pulmonary artery. Life Sciences, 1995, 56, 1045.	4.3	0
107	Leukotriene synthesis inhibition and anti-ige challenge of human lung parenchyma. Life Sciences, 1996, 59, PL213-PL219.	4.3	0
108	Acetylcholine induces a greater production of prostacyclin in human pulmonary arteries than in veins. Journal of Physiology (Paris), 1998, 92, 507-508.	2.1	0

#	Article	IF	Citations
109	Increased Human Vascular Reactivity Via Cyclooxygenase-2 Inhibition During Acute Inflammation: Role of Prostaglandins E2 and I2. Inflammation Research, 2009, 58, S249-S251.	4.0	0
110	Editorialâ€"Special issue of the 6th European Workshop on Lipid Mediators. Prostaglandins and Other Lipid Mediators, 2017, 133, 1-3.	1.9	0
111	Prostaglandin Endoperoxide H Synthase-2 (PGHS-2) Variants and Risk of Obesity and Microvascular Dysfunction Among Tunisians: Relevance of rs5277 (306G/C) and rs5275 (8473T/C) Genetic Markers. Biochemical Genetics, 2021, 59, 1457-1486.	1.7	0
112	Leukotrienes and the Pulmonary Vascular Bed. Advances in Experimental Medicine and Biology, 2002, 507, 309-313.	1.6	0
113	Arachidonic Acid Inhibits Cysteinyl-Leukotriene Receptor Activation in Human Pulmonary Vessels. Advances in Experimental Medicine and Biology, 2003, 525, 75-79.	1.6	0
114	Cholinesterase Activities in Intact Human Pulmonary Vessels Treated with LTD4. , 1998, , 594-595.		0
115	Cysteinyl-Leukotrienes and the Human Lung. Advances in Experimental Medicine and Biology, 1999, 447, 171-179.	1.6	0
116	Prostanoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	0